Please assess the completion status of the following clinical trial:

Trial Title: Belatacept for Renal Transplant Recipients With Delayed Graft Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed Written Informed Consent~2. Deceased donor renal transplant recipient~3. Men and women, aged 18-60 years of age~Exclusion Criteria:~1. Seronegative or unknown EBV serostatus~2. Patients unwilling or incapable of providing informed consent.~3. Patients with active tuberculosis or positive TB test without evidence of infection treatment.~4. Patients with demonstrated acute rejection on first biopsy evaluation for delayed graft function; Second transplant or multiple organ transplant; patients more than 12 days post renal transplant prior to enrollment~5. Evidence of Sepsis or other clinical indicators deemed clinically contraindicated for study enrollment by the primary physician~6. Inadequate vein access to receive monthly IV infusions~7. Prior proven allergy or severe adverse drug reaction to mycophenolate, steroid or Belatacept preventing therapy.~8. Pregnant women or women of child bearing age not willing to commit to dual contraception prophylaxis~9. Use of alemtuzumab (Campath 1-H©), basilixumab (Simulect©) and daclizumab (Zenapax©) are not permitted in this protocol; Use of other immunosuppressive agents must be limited to those specified in this protocol.~10. Prisoners or subjects who are involuntarily incarcerated.~11. Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness.~12. Pre-sensitized patients with alloscreen antibody levels of 80% or more class I or class II

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Belatacept (Type: ACTIVE_COMPARATOR): Belatacept 10mg/kg administered intravenously on days 1, 4, 15, and 28, weeks 8 and 12. Then continue at 5mg/kg every 4 weeks throughout the completion of the study.
- Everolimus (Type: ACTIVE_COMPARATOR): Everolimus 1.5 mg/kg twice a day by mouth, the dose will be adjusted after Day 3.

Based on this trial design, predict the completion outcome and termination type (if applicable).